$53.86▾ 4.26%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$-1.07BTTM operating cash
Pre-profit
It is still burning cash while pre-profit.
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
+2.1%year over year
Watch
Revenue growth has flattened.
Leverage
Not enough data yet
Term-debt data is not available for this company.
More coming: dilution / share-count creep.
✦ The read
Moderna, Inc. is pre-profit. It is still burning cash while pre-profit. Revenue growth has flattened.
Key numbers
Valuation
EPS (TTM)$-7.99
TTM (trailing 12 months, through fiscal Q2 FY2026)
Profitability
Net margin-141.4%
TTM (trailing 12 months, through fiscal Q2 FY2026)
Size
Revenue (TTM)$2.23B
TTM (trailing 12 months, through fiscal Q2 FY2026)
Recent news
Sentiment · last 30 days5 articles
2 bullish3 neutral0 bearish
After Soaring Nearly 90% Thus Far in 2026, Is Moderna's Stock Still a Buy?
IXJ vs. RSPH: Which Healthcare ETF Is the Better Buy?
Moderna Is Up 109% in 2026. Jim Cramer Just Called It 'Finally Investable Again.' Is the Stock a No-Brainer Buy on Its Recent Pullback?Clinical Stage Partnering Terms and Agreements in Pharmaceuticals and Biotechnology 2020-2026 | Benchmark More Than 1,800 Biopharma Deals with Various Indexes
Vertex Pharmaceuticals Just Made a $10 Billion Move. Is the Stock a Buy?
Signals and key numbers are from the fiscal Q2 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.